Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
 |
Anesiva Announces Going Concern Opinion and Nasdaq Notice
Apr 1, 2009
|
10.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV), a specialty pharmaceutical company focused on pain management, today announced that its consolidated financial statements for the fiscal year ended December 31, 2008, included in the Company's annual report on Form 10-K filed w...
|
|
 |
Anesiva Announces Planned Rights Offering
Mar 26, 2009
|
9.9 KB
|
| |
SOUTH SAN FRANCISCO, Calif., March 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV), a specialty pharmaceutical company focused on pain management, announced today that it is planning to commence a rights offering of notes to its stockholders, which, would if fully subscribed, produce gross proceeds to Anesiva...
|
|
 |
Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
Jan 9, 2009
|
9.2 KB
|
| |
SOUTH SAN FRANCISCO, Jan 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc.
(Nasdaq: ANSV) today announced that the U.S. Food and Drug Administration
(FDA) has approved Anesiva's supplemental New Drug Application (sNDA) to
expand the indication for Zingo(TM) to treat the pain associated with blood
draws to include adults. ...
|
|
 |
Anesiva Announces Changes to Its Board of Directors and Receives Notification From Nasdaq
Dec 19, 2008
|
10.1 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva,
Inc. (Nasdaq: ANSV), a specialty pain management company, announced today that
consistent with its recent announcement of a positive Phase 3 clinical trial
for Adlea(TM) and to focus on this asset by going to a virtual company model,
five member...
|
|
 |
Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
Dec 16, 2008
|
12.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva,
Inc. (Nasdaq: ANSV) today announced top-line results showing that the Phase 3
trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug
candidate, achieved its primary efficacy endpoint of reducing post-surgical
pain versus placebo ...
|
|
|